Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;17(Suppl 2):S579-83.
doi: 10.4103/2230-8210.122142.

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the West Bengal cohort of the A1chieve study

Satinath Mukhopadhyay  1 , Nilanjan Sengupta  2 , Sujoy Ghosh  1
Affiliations

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the West Bengal cohort of the A1chieve study

Satinath Mukhopadhyay et al. Indian J Endocrinol Metab. 2013 Nov.

Abstract

Background: The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents.

Materials and methods: Data was collected at baseline, 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from West Bengal, India.

Results: A total of 1133 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 897), insulin detemir (n = 94), insulin aspart (n = 90), basal insulin plus insulin aspart (n = 28) and other insulin combinations (n = 19). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 8.5%) and insulin user (mean HbA1c: 8.9%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA1c (insulin naïve: -1.3%, insulin users: -1.6%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.

Conclusion: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.

Keywords: A1chieve study; West Bengal; insulin analogues; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53. - PubMed
    1. Shetty P. Public health: India's diabetes time bomb. Nature. 2012;485:S14–6. - PubMed
    1. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(Suppl 3):S18–24. - PubMed
    1. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174–83. - PubMed
    1. Shah SN, Litwak L, Haddad J, Chakkarwar PN, Hajjaji I. The A1chieve study: A 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice. Diabetes Res Clin Pract. 2010;88(Suppl 1):S11–6. - PubMed